Bio-Path Holdings, Inc.
Index- P/E- EPS (ttm)-1.60 Insider Own0.47% Shs Outstand7.16M Perf Week2.72%
Market Cap29.62M Forward P/E- EPS next Y-1.60 Insider Trans0.00% Shs Float7.13M Perf Month2.21%
Income-11.40M PEG- EPS next Q-0.49 Inst Own5.30% Short Float0.73% Perf Quarter46.48%
Sales- P/S- EPS this Y45.10% Inst Trans-3.33% Short Ratio1.48 Perf Half Y11.53%
Book/sh3.12 P/B1.33 EPS next Y15.30% ROA-40.40% Target Price11.00 Perf Year-37.63%
Cash/sh2.98 P/C1.40 EPS next 5Y- ROE-42.50% 52W Range2.68 - 8.62 Perf YTD10.34%
Dividend- P/FCF- EPS past 5Y36.10% ROI- 52W High-51.86% Beta1.47
Dividend %- Quick Ratio15.10 Sales past 5Y- Gross Margin- 52W Low54.85% ATR0.20
Employees10 Current Ratio15.10 Sales Q/Q- Oper. Margin- RSI (14)60.56 Volatility4.16% 5.07%
OptionableYes Debt/Eq0.00 EPS Q/Q-9.70% Profit Margin- Rel Volume0.28 Prev Close4.16
ShortableYes LT Debt/Eq0.00 EarningsAug 16 BMO Payout- Avg Volume35.23K Price4.15
Recom2.00 SMA208.24% SMA507.79% SMA2009.38% Volume4,941 Change-0.24%
Mar-11-21Initiated ROTH Capital Buy $13
Nov-13-17Reiterated H.C. Wainwright Buy $4.50 → $1.50
Aug-10-16Reiterated Maxim Group Buy $5 → $2
Apr-18-16Initiated Rodman & Renshaw Buy $5
Jun-02-14Resumed Maxim Group Buy $5
May-09-14Initiated Maxim Group Buy $5
Aug-09-22 07:00AM  
Jun-13-22 12:10PM  
May-17-22 07:00AM  
May-16-22 07:51AM  
May-10-22 07:00AM  
Apr-13-22 04:30PM  
Apr-12-22 04:01PM  
Apr-06-22 07:00AM  
Mar-11-22 07:00AM  
Mar-08-22 04:30PM  
Mar-04-22 07:00AM  
Jan-05-22 07:00AM  
Dec-13-21 07:00AM  
Dec-06-21 04:22AM  
Nov-12-21 07:00AM  
Nov-05-21 08:00AM  
Nov-04-21 09:01AM  
Oct-27-21 07:00AM  
Sep-20-21 04:30PM  
Aug-25-21 10:24AM  
Aug-24-21 11:00AM  
Aug-13-21 07:00AM  
Aug-06-21 07:00AM  
Jun-22-21 07:00AM  
Jun-15-21 03:22PM  
Jun-09-21 01:56AM  
May-27-21 08:00AM  
May-14-21 07:00AM  
May-07-21 07:00AM  
Apr-26-21 09:00AM  
Apr-22-21 07:00AM  
Apr-12-21 07:00AM  
Apr-05-21 08:03AM  
Mar-11-21 07:00AM  
Mar-10-21 07:00AM  
Mar-03-21 04:01PM  
Feb-18-21 04:01PM  
Feb-16-21 07:15AM  
Feb-13-21 07:00AM  
Feb-10-21 07:08AM  
Dec-21-20 02:05PM  
Dec-11-20 03:48AM  
Nov-19-20 07:00AM  
Nov-13-20 07:00AM  
Nov-06-20 08:00AM  
Oct-22-20 07:00AM  
Sep-18-20 12:00PM  
Sep-09-20 08:00AM  
Aug-14-20 07:00AM  
Aug-13-20 07:00AM  
Aug-07-20 08:00AM  
Jun-25-20 11:28PM  
Jun-17-20 07:30AM  
May-29-20 08:00AM  
May-15-20 07:00AM  
May-13-20 05:00PM  
May-08-20 08:00AM  
Apr-27-20 09:00AM  
Apr-13-20 07:00AM  
Mar-13-20 07:39PM  
Mar-11-20 07:00AM  
Mar-06-20 07:00AM  
Feb-28-20 08:00AM  
Feb-21-20 10:34AM  
Jan-23-20 09:07AM  
Jan-08-20 08:00AM  
Dec-06-19 09:25AM  
Dec-05-19 09:42PM  
Dec-04-19 12:00PM  
Nov-26-19 08:00AM  
Nov-25-19 02:11PM  
Nov-21-19 11:30AM  
Nov-15-19 07:00AM  
Nov-08-19 08:00AM  
Oct-29-19 06:47AM  
Oct-16-19 02:29PM  
Oct-15-19 08:00AM  
Sep-25-19 08:00AM  
Sep-14-19 09:36AM  
Sep-04-19 01:10AM  
Sep-03-19 04:01PM  
Aug-26-19 07:00AM  
Aug-15-19 07:00AM  
Aug-08-19 04:01PM  
Jul-17-19 11:39AM  
Jul-16-19 08:18AM  
Jun-04-19 11:51AM  
May-16-19 07:05AM  
May-15-19 08:16AM  
May-10-19 04:01PM  
Bio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused RNAi nano particle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction. Its lead drug candidate is prexigebersen, which is in Phase II clinical trials for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome. It is also developing Liposomal Bcl-2 for the treatment of refractory/relapsed lymphoma and chronic lymphocytic leukemia; Liposomal STAT3 that is in preclinical stage for the treatment of pancreatic cancer, non-small cell lung cancer, and AML; and prexigebersen-A for various solid tumors. Bio-Path Holdings, Inc. was founded in 2007 and is based in Bellaire, Texas.